William Blair Predicts Amgen’s Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at William Blair decreased their Q4 2024 earnings per share estimates for shares of Amgen in a note issued to investors on Tuesday, January 21st. William Blair analyst M. Phipps now expects that the medical research company will post earnings per share of $5.05 for the quarter, down from their prior estimate of $5.12. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.57 per share. William Blair also issued estimates for Amgen’s FY2025 earnings at $21.34 EPS.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the business posted $4.96 EPS. The business’s quarterly revenue was up 23.2% on a year-over-year basis.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft lowered their price objective on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Bank of America restated an “underperform” rating and issued a $256.00 target price on shares of Amgen in a report on Tuesday, December 10th. Citigroup lowered their price target on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Finally, Wells Fargo & Company cut their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.91.

Amgen Stock Performance

Amgen stock opened at $273.44 on Wednesday. The firm has a fifty day simple moving average of $272.47 and a two-hundred day simple moving average of $306.67. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a market capitalization of $146.98 billion, a PE ratio of 35.01, a P/E/G ratio of 2.78 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.48%. Amgen’s dividend payout ratio is currently 115.24%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BSW Wealth Partners increased its stake in shares of Amgen by 3.5% during the fourth quarter. BSW Wealth Partners now owns 2,371 shares of the medical research company’s stock valued at $618,000 after purchasing an additional 81 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Amgen by 1.6% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,382 shares of the medical research company’s stock valued at $1,142,000 after buying an additional 67 shares in the last quarter. Tamar Securities LLC boosted its holdings in Amgen by 8.6% in the fourth quarter. Tamar Securities LLC now owns 57,088 shares of the medical research company’s stock worth $14,879,000 after acquiring an additional 4,537 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Amgen by 25.1% during the fourth quarter. Perigon Wealth Management LLC now owns 16,145 shares of the medical research company’s stock valued at $4,350,000 after acquiring an additional 3,236 shares in the last quarter. Finally, Jeppson Wealth Management LLC boosted its stake in Amgen by 30.4% in the 4th quarter. Jeppson Wealth Management LLC now owns 3,487 shares of the medical research company’s stock worth $909,000 after purchasing an additional 812 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.